Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$73.1 million.

  • Ascendis Pharma A's Net Income towards Common Stockholders fell 16713.68% to -$73.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$168.3 million, marking a year-over-year decrease of 16142.29%. This contributed to the annual value of -$409.2 million for FY2024, which is 2144.78% up from last year.
  • Per Ascendis Pharma A's latest filing, its Net Income towards Common Stockholders stood at -$73.1 million for Q3 2025, which was down 16713.68% from $45.6 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Net Income towards Common Stockholders ranged from a high of $176.6 million in Q3 2023 and a low of -$211.6 million during Q4 2022
  • Its 5-year average for Net Income towards Common Stockholders is -$28.3 million, with a median of -$75.7 million in 2021.
  • In the last 5 years, Ascendis Pharma A's Net Income towards Common Stockholders crashed by 25224.72% in 2023 and then surged by 21873.17% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Net Income towards Common Stockholders (Quarter) stood at -$121.3 million in 2021, then plummeted by 74.41% to -$211.6 million in 2022, then surged by 55.07% to -$95.1 million in 2023, then surged by 56.77% to -$41.1 million in 2024, then plummeted by 77.92% to -$73.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$73.1 million in Q3 2025, compared to $45.6 million in Q2 2025 and -$99.6 million in Q1 2025.